India’s leading drug maker Dr. Reddy’s Laboratories said that it has entered into an agreement with Swiss-pharma major Novartis to acquire the cardiovascular brand Cidmus in India for Rs 456 crore ($61 million). Under the agreement, Dr. Reddy’s will be assigned and transferred the Cidmus trademark in India from Novartis. The Cidmus brand is a combination of high blood pressure drug valsartan and antihypertensive drug sacubitril (currently under Novartis patent) which is indicated for heart failure patients with reduced ejection fraction.